Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 267-744-8 | CAS number: 67914-60-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Toxicokinetic assessment of T001141
T001141 (CAS 67914-60-7) is a white, beige odourless powder with a moderate molecular weight (220.27 g/mol), a particle size of 597.669 µm (Mass Median Aerodynamic Diameter or MMAD), a high water solubility (3.35 g/L), a moderate partition coefficient (log Kow <0.3) and a low volatility (vapour pressure of <2.1 E-11 kPa at 25°C).
The structure and pKa values indicate that the product is not ionized at neutral pH. Based on the physicochemical data and toxicity studies, the oral absorption factor is set to 100%, and the dermal absorption factor is set to 50%. The respiratory absorption factor is set to 50% based on the physicochemical properties.
The assessment is described in the section underneath ("Additional information").
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 50
Additional information
Toxicokinetic assessment of T001141
T001141 (CAS 67914-60-7) is a white, beige odourless powder with a moderate molecular weight (220.27 g/mol), a particle size of 597.669 µm (Mass Median Aerodynamic Diameter or MMAD), a high water solubility (3.35 g/L), a moderate partition coefficient (log Kow <0.3) and a low volatility (vapour pressure of <2.1 E-11 kPa at 25°C).
The backbone of T001141 is a piperazine group, with a methoxygroup and a hydroxyphenylgroup attached to the first and second nitrogen respectively. The presence of nitrogen within the piperazine group can lead to a weak alkaline character, while the phenol group has a weak acidic character which can be confirmed by the calculated pKa values based on the Perrin calculation method (Reingruber, 2017). Therefore, it is estimated that the product is not ionized at neutral pH.
No toxicokinetic data (animal or human studies) are available on this substance. The data present in this dossier are based on physicochemical and toxicological parameters and will allow a qualitative assessment of the toxicokinetic behaviour of T001141.
Absorption
Oral/GI absorption:
T001141 is considered favorable for absorption since it has a moderate molecular weight (< 500 g/mol), a moderate log Kow value (between -1 and 4) and a high water solubility (3.35 g/L) leading to dissolution of the substance into the gastrointestinal fluids and absorption through passive diffusion. It is generally assumed that the absorption along the gastrointestinal tract predominantly takes place in the small intestine. Based on the calculated pKa values, no ionization of T001141 is expected in the relevant pH range.
A combined 28-day repeated dose toxicity with the reproductive/developmental toxicity screening test (OECD 422; Peter, 2017) has been performed by oral gavage with T001141 on Wistar Han rats at the dose levels 0, 50, 150 and 500 mg/kg bodyweight/day. Significant general toxicity was observed in males and females treated at 500 mg/kg/day such as clinical signs of toxicity, reduced body weight gain and food consumption, adverse morphological changes in the spleen with associated changes in blood parameters, decreased number of circulating total white blood cells and adverse morphological changes in the thyroid gland and bone marrow in both sexes and adverse morphological findings in the thymus, testes and epididymides in males only.
At a dosage of 500 mg/kg/day, there were no females with live offspring. No abnormalities were observed in the reproductive organs of femals treated with 500 mg/kg/day, this observation was attributed to the severe effects observed on the testes (abnormal spermatogenesis). No test-item related reproduction toxicity and no developmental toxicity was observed at 50 and 150 g/kg/day. Possible developmental toxicity at 500 mg/kg/day could not be evaluated because none of the two pregnant females treated at 500 mg/kg/day had offspring. The parental, reproduction and developmental NOAEL (No Observed Adverse Effect Level) were set to 150 mg/kg/day.
From an acute oral toxicity study (OECD 423; Latour, 2016) in which 2000 mg/kg body weight and 300 mg/kg bodywheight was applied to Wistar rats, it could be derived that the LD50 was in the range of 300 – 2000 mg/kg bodyweight, with a cut-off value of 2000 mg/kg bodyweight. Based on this observation, T001141 is considered harmful if swallowed.
Based on the physicochemical properties and the results of the toxicity studies, the oral absorption factor is set to 100%.
Respiratory absorption:
Given its low volatility, the availability of T001141 for inhalation as a vapour is limited. Based on the fact that its aerodynamic diameter is larger than 100 µm, the solid particles have no or very limited potential to be inhaled (no presence of inhalable or respirable particles).
Based on the other physicochemical properties, T001141 can diffuse/dissolve into the mucus lining the respiratory tract, since it is a highly water soluble powder. Its slightly lipophilic character (logKow>0) implies that the product has the potential to be subsequently absorbed directly across the respiratory tract epithelium through passive diffusion. The portion of the product which is not dissolved into the mucus could be coughed or sneezed out of the body or swallowed. As described above, the product has the potential to be absorbed after oral intake. However, based on the fact that the mass median aerodynamic diameter is so high, little respiratory absorption is expected (as described above).
Therefore, the respiratory absorption factor is set to 50%.
Dermal absorption:
T001141 is a solid substance and therefore not readily taken up by the skin in comparison to liquid products. The product will have to dissolve into the surface moisture of the skin before uptake can take place. Based on its high water solubility (3.35 g/L), dermal uptake is expected to be moderate to high since the substance is sufficiently soluble in water to partition from the stratum corneum into the epidermis. The moderate logKow value of <0.3 indicates that the substance is slightly lipophilic and therefore easily crosses the lipid rich environment of the stratum corneum leading to dermal uptake.
An acute dermal toxicity study (OECD 402; Latour, 2016) with Wistar rats to which a single dose of 2000 mg/kg was applied, showed no effects related to the test material. Based on anin vivoskin irritation test on New Zealand White rabbits (OECD 404; SafePharm Laboratories Ltd., 2004). T001141 was found to be a mild irritant and should not be classified as irritant (mean score was below the cut-off value) which implies that no enhanced penetration can be caused by damage to the skin.
As a result, the dermal absorption factor for T001141 is set to 50%.
Distribution
The high water solubility and moderate molecular weight predict that T001141 will probably distribute through the body due to diffusion through aqueous channels and pores. Since the substance is slightly lipophilic (logKow>0), the substance is likely to distribute into cells leading to a higher intracellular concentration in comparison to the extracellular concentration particularly in fatty tissues. The conclusions of the oral toxicity study indicate that the target organs are mainly the thyroid gland and spleen (andin the thymus, testes and epididymides in males only).
Accumulation
Since T001141 is only slightly lipophilic (log Kow <0.3), accumulation is considered unlikely.
Metabolism
Based on the structure, T001141 might undergo phase I biotransformation such as oxidation and reduction followed by conjugation reactions (phase II) such as glucuronidation (by the enzyme glucuronosyltransferase) and sulfation (by the enzyme sulfotransferase. The Phase II conjugation reactions largely increase the hydrophilic character of the product. Metabolism mainly takes place in the liver, causing route specific presystemic (or first pass) effects, especially after oral intake. Other metabolic changes may take place in the gastrointestinal (GI) flora or within the GI tract epithelia (mainly in the small intestine), respiratory tract epithelia (in the nasal cavity, trachea-bronchial mucosa and alveoli and skin), etc.
Excretion
Given its high water solubility and molecular weight <300, the most likely route of excretion of T001141 from the systemic circulation is the urine. In general, conjugated metabolites such as glucuronides and sulfates from Phase II biotransformation reactions are excreted in the urine. Most of them will have been filtered out from the blood by the kidneys, though a small amount can enter the urine directly by passive diffusion. There is also the potential for re-absorption into the systemic circulation across the tubular epithelium. Another route of excretion of conjugated derivatives (such as glucuronides) is the bile. The excretion via the bile is highly influenced by hepatic function since metabolites formed in the liver may be excreted directly into the bile without entering the bloodstream. Products in the bile pass through the intestine before excretion in the faeces and can thus undergo enterohepatic recycling which will prolong their half-life. Furthermore, T001141 can be excreted in the saliva (where in can be swallowed again) or in the sweat since it is non-ionized and slightly lipid soluble.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.